Institute For Medical Education and Research (IMER)

md oncology melanoma ipilimumab cancer cml metastatic chronic myelogenous leukemia ovarian cancer ovarian endocrinopathies breast cancer docetaxel bevacizumab prostate cancer braf inhibitor phd immuno-oncology imatinib cytogenetic response fish iris study so325 trial design tops trial mutational analysis chronic michael w. n. deininger leukemia anti-ctla4 antibody perifosine/bortezomib lenalidomide venous thromboembolic events gcsf bortezomib vte calgb 100104 schema maintenance therapy cyclophosphamide pat killingsworth crab page bertolotti sundar jagannath beth faiman hypogammaglobulinemia multiple myeloma prospect trial tropic trial diphenhydramine ketoconazole tax 327 crpc cabazitaxel-prednisone swog 9916 castration-resistant maurie markman md cisplatin carboplatin vismodegib hedgehog inhibitor basal cell carcinoma jean y. tang myelogenous bcr-abl hpv status anti-angiogenic agents egfr inhibitors hnc marshall r. posner head and neck dexamethasone emmanuel antonarakis abiraterone dr. a. oliver sartor cabazitaxel leonard gomella immunotherapy sipuleucel-t pi3k/mtor inhibitors combination therapy estrogen endocrine-resistance vegf pathway antiangiogenic agents antiangiogenesis pdgf therapies fgf vegf antiangiogenic iraes imer gi dacarbazine mek inhibitors braf immune-related adverse events. vaccines immunotherapies non-small cell lung cancer anti-ctla-4 renal cell carcinoma her2 positive anthracyclines hormonal therapy her2+ her2-targeted therapy endocrine therapy adjuvant therapy receptor targeted therapy positive aromatase inhibitors advanced mapk pathway hypophysitis kaplan-meier analysis peg esper mdx010-20 krista m. rubin vemurafenib sokal hasford scoresdasatinib ipilimumab tyrosine kinase inhibitors tkis dasatinib nilotinib kathleen k. curran mollie e. moran michael r. savona philadelphia chromosome bcc ctla4 inhibitors antoni ribas md cancer care john powderly ii androgen-ablation charles g. drake imiquimod cd8+ cytotoxic t lymphocyte prostate ctla-4 tlr ligands tumor antigens tremelimumab thomas f. gajewski jorge e. cortes jerald p. radich michael wn deininger evan m. hersh md